Antiproliferation effects of ~(188)Re labeled monoclonal antibody on prostate cancer cells in vitro
- VernacularTitle:~(188)Re-7E11C5.3抑制前列腺癌细胞增殖
- Author:
Weizhen CHEN
;
Yong ZHANG
;
Hanping LU
;
Changsheng LIANG
;
Yao XIE
;
Changzheng LIU
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Radioimmunotherapy;
Antibodies,monoclonal;
Prostate-specific membrane antigen;
Rhenium-188
- From:
Chinese Journal of Pathophysiology
2000;0(10):-
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To investigate the effect of 188Re labeled monoclonal antibody on prostatic specific membrane antigen 7E11C5.3,radioimmunotherapy for the treatment of human prostate cancer cell line LNCaP in vitro.METHODS: 188Re-7E11C5.3 was prepared by direct 2-mercaptoethanol reduction method.Labeling efficiency and radiochemical purity was measured by paper chromatography.Immunoreactive fraction was determined by linear extrapolation.Cytotoxicity to LNCaP cells was determined by MTT assay.RESULTS: The labeling yield of 188Re-7E11C5.3 was(93.16?2.18)%,the radiochemical purity was(95.62?0.48)%,and the immunoreactive fraction was(74.86?1.86)%.The inhibitory effect of 188Re-7E11C5.3 on cell proliferation of LNCaP cells was significantly higher than that of 188Re-mIgG or 188ReO-4.The 50% inhibitory doses(IC50) of 188Re-7E11C5.3,188Re-mIgG,and 188ReO-4 were(23.38?3.73)?107 Bq/L,(59.21?8.02)?107 Bq/L and(68.89?10.91)?107 Bq/L,respectively.CONCLUSION: 188Re-7E11C5.3 can effectively inhibit the growth of in vitro cultured prostate cancer cells and shows much potential for prostate cancer radioimmunotherapy.
